A panel of US respiratory experts has voted in favour of approving an experimental inhaler drug from GlaxoSmithKline and Theravence for treating chronic lung disease.
A majority of Food and Drug Administration panelists voted that the Breo Ellipta inhaler is safe and effective for long-term use and to control flare ups in patients with chronic obstructive pulmonary disorder.
The FDA is not required to follow the group's recommendation, though it often does.
The ailment, often called smoker's cough, can cause a number of breathing problems, including chronic bronchitis and emphysema.
Breo is a combination of two respiratory drugs that help to open lung airways and reduce swelling. The combination drug is designed to be used with the Ellipta inhaler device.